Donaldson Company (DCI) Q4 2024 earnings summary

Executive summary

• Achieved record sales and earnings for both Q4 and full year 2024, with full-year sales surpassing $3.5 billion and adjusted EPS up 13% to $3.42.

• Returned $286 million to shareholders in FY24 and $82 million in Q4 via dividends and share repurchases, maintaining cash conversion above 97%.

• Completed acquisition of a 49% stake in Medica S.p.A. to strengthen Life Sciences capabilities.

• Advanced 2030 ESG ambitions and increased R&D investment by 16% over prior year.

• Launched footprint and cost optimization programs to drive long-term growth.

Financial highlights

• Q4 sales grew 6% year-over-year to $935 million, with adjusted EPS up 21% to $0.94 and operating margin up 200 basis points.

• Gross margin for Q4 was 36.2%, up 190 basis points; operating margin reached 16.3%.

• FY24 sales were $3.59 billion, up 5% year-over-year; adjusted diluted EPS increased 13% to $3.42.

• Free cash flow for FY24 was $408 million, with cash conversion above 97%.

• Paid $122.8 million in dividends and repurchased 2% of outstanding shares for $163.3 million in FY24.

Outlook and guidance

• Fiscal 2025 sales expected to increase 2%-6%, with adjusted operating margin between 15.3%-15.9% and adjusted EPS of $3.56-$3.72.

• Updated fiscal 2026 targets: consolidated sales CAGR of 3%-7%, operating margin of 15.8%-16.6%.

• Mobile Solutions and Industrial Solutions sales outlook unchanged; Life Sciences sales CAGR reduced to 12%-16% with profitability between 5%-11%.

• R&D investments and capital expenditures to continue increasing, with capex projected at $85-$105 million in 2025.

• Free cash flow conversion targeted at 85%-95%.